Advanced search
Publication Cover
Neurobehavioral HIV Medicine Volume 4, 2012 - Issue
Journal homepage
14
Views
0
CrossRef citations to date
0
Altmetric
Review

HIV treatment: mechanisms of neurotoxicity and implications for targeted therapy

Chengxiang Wu1 Department of Microbiology;2 Department of Public Health Sciences, University of Hawai’i, Honolulu, HI, USACorrespondence[email protected]
&
Yuanan Lu1 Department of Microbiology;2 Department of Public Health Sciences, University of Hawai’i, Honolulu, HI, USA
Pages 75-98 | Published online: 04 Sep 2012

References

  • Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med. 2009;60:471–484.
  • Joint United Nations Program on HIV/AIDS. Report on the Global AIDS Epidemic 2006. Geneva: UNAIDS 2006.
  • Joint United Nations Program on HIV/AIDS. Report on the Global AIDS Epidemic 2010. Geneva: UNAIDS; 2010.
  • Cunningham AL, Donaghy H, Harman AN, Kim M, Turville SG. Manipulation of dendritic cell function by viruses. Curr Opin Microbiol. 2010;13(4):524–529.
  • Migueles SA, Connors M. Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV. JAMA. 2010;304(2):194–201.
  • Gray F, Adle-Biassette H, Chretien F, Lorin de la Grandmaison G, Force G, Keohane C. Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-associated disorders and modifications according to treatments. Clin Neuropathol. 2001;20(4): 146–155.
  • Gonzalez RG, Cheng LL, Westmoreland SV, et al. Early brain injury in the SIV-macaque model of AIDS. AIDS. 2000;14(18): 2841–2849.
  • Powderly WG. Current approaches to treatment for HIV-1 infection. J Neurovirol. 2000;6(Suppl 1):S8–S13.
  • McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005;4(9):543–555.
  • Jones G, Power C. Regulation of neural cell survival by HIV-1 infection. Neurobiol Dis. 2006;21(1):1–17.
  • Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature. 2001;410(6831):988–994.
  • Kaul M, Zheng J, Okamoto S, Gendelman HE, Lipton SA. HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differ. 2005;12(Suppl 1):S878–S892.
  • Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res. 2005;111(2):194–213.
  • Lavi E, Kolson DL, Ulrich AM, Fu L, Gonzalez-Scarano F. Chemokine receptors in the human brain and their relationship to HIV infection. J Neurovirol. 1998;4(3):301–311.
  • Miller RJ, Meucci O. AIDS and the brain: is there a chemokine connection? Trends Neurosci. 1999;22(10):471–479.
  • Minghetti L. Role of inflammation in neurodegenerative diseases. Curr Opin Neurol. 2005;18(3):315–321.
  • Everall IP, Hansen LA, Masliah E. The shifting patterns of HIV encephalitis neuropathology. Neurotox Res. 2005;8(1–2):51–61.
  • James HJ, Sharer LR, Zhang Q, et al. Expression of caspase-3 in brains from paediatric patients with HIV-1 encephalitis. Neuropathol Appl Neurobiol. 1999;25(5):380–386.
  • Masliah E, DeTeresa RM, Mallory ME, Hansen LA. Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS. 2000;14(1):69–74.
  • Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18): 1789–1799.
  • McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol. 2010;67(6):699–714.
  • Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17(1):3–16.
  • Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23):2087–2096.
  • Bhaskaran K, Mussini C, Antinori A, et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol. 2008;63(2): 213–221.
  • Lescure FX, Omland LH, Engsig FN, et al. Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis. 2011;52(2):235–243.
  • McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology. 1993;43(11):2245–2252.
  • Chakravarty S, Herkenham M. Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines. J Neurosci. 2005;25(7):1788–1796.
  • Turrin NP, Rivest S. Unraveling the molecular details involved in the intimate link between the immune and neuroendocrine systems. Exp Biol Med (Maywood). 2004;229(10):996–1006.
  • Cunningham PH, Smith DG, Satchell C, Cooper DA, Brew B. Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS. 2000;14(13):1949–1954.
  • Hesselgesser J, Taub D, Baskar P, et al. Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 alpha is mediated by the chemokine receptor CXCR4. Curr Biol. 1998;8(10):595–598.
  • Kaul M, Ma Q, Medders KE, Desai MK, Lipton SA. HIV-1 coreceptors CCR5 and CXCR4 both mediate neuronal cell death but CCR5 paradoxically can also contribute to protection. Cell Death Differ. 2007;14(2):296–305.
  • Bunnik EM, Swenson LC, Edo-Matas D, et al. Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing. PLoS Pathog. 2011;7(6):e1002106.
  • Lazarini F, Tham TN, Casanova P, Arenzana-Seisdedos F, Dubois-Dalcq M. Role of the alpha-chemokine stromal cell-derived factor (SDF-1) in the developing and mature central nervous system. Glia. 2003;42(2):139–148.
  • van der Meer P, Ulrich AM, Gonzalez-Scarano F, Lavi E. Immunohistochemical analysis of CCR2, CCR3, CCR5, and CXCR4 in the human brain: potential mechanisms for HIV dementia. Exp Mol Pathol. 2000;69(3):192–201.
  • Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray PW, Miller RJ. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci U S A. 1998;95(24):14500–14505.
  • Kaul M, Lipton SA. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci U S A. 1999;96(14):8212–8216.
  • Kruman II, Nath A, Mattson MP. HIV-1 protein Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. Exp Neurol. 1998;154(2) :276–288.
  • McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol. 2004;157(1–2):3–10.
  • Choi WT, Kaul M, Kumar S, et al. Neuronal apoptotic signaling pathways probed and intervened by synthetically and modularly modified (SMM) chemokines. J Biol Chem. 2007;282(10):7154–7163.
  • Brooks JT, Kaplan JE, Masur H. What’s new in the 2009 US guidelines for prevention and treatment of opportunistic infections among adults and adolescents with HIV? Top HIV Med. 2009;17(3):109–114.
  • McArthur JC. Neurologic manifestations of AIDS. Medicine (Baltimore). 1987;66(6):407–437.
  • Glass JD, Wesselingh SL. Microglia in HIV-associated neurological diseases. Microsc Res Tech. 2001;54(2):95–105.
  • Langford TD, Letendre SL, Larrea GJ, Masliah E. Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol. 2003;13(2):195–210.
  • Kraft-Terry SD, Stothert AR, Buch S, Gendelman HE. HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol Dis. 2010;37(3):542–548.
  • Johnson T, Nath A. Neurological complications of immune reconstitution in HIV-infected populations. Ann N Y Acad Sci. 2010;1184:106–120.
  • French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis. 2009;48(1):101–107.
  • Miller RF, Isaacson PG, Hall-Craggs M, et al. Cerebral CD8+ lymphocytosis in HIV-1 infected patients with immune restoration induced by HAART. Acta Neuropathol. 2004;108:17–23.
  • Anneken K, Fischera M, Evers S, Kloska S, Husstedt IW. Recurrent vacuolar myelopathy in HIV infection. J Infect. 2006;52(6): e181–e183.
  • Di Rocco A, Simpson DM. AIDS-associated vacuolar myelopathy. AIDS Patient Care STDS. 1998;12(6):457–461.
  • Singer EJ, Valdes-Sueiras M, Commins D, Levine A. Neurologic presentations of AIDS. Neurol Clin. 2010;28(1):253–275.
  • Aboulafia DM, Taylor L. Vacuolar myelopathy and vacuolar cerebellar leukoencephalopathy: a late complication of AIDS after highly active antiretroviral therapy-induced immune reconstitution. AIDS Patient Care STDS. 2002;16(12):579–584.
  • Schmidbauer M, Budka H, Okeda R, Cristina S, Lechi A, Trabattoni GR. Multifocal vacuolar leucoencephalopathy: a distinct HIV-associated lesion of the brain. Neuropathol Appl Neurobiol. 1990;16(5):437–443.
  • Bassiri A, Holden J, Wong M. A case of fulminant human immunodeficiency virus dementia. Clin Infect Dis. 1995;21(5): 1313–1314.
  • Berger JR, Arendt G. HIV dementia: the role of the basal ganglia and dopaminergic systems. J Psychopharmacol. 2000;14(3):214–221.
  • Avison MJ, Nath A, Greene-Avison R, Schmitt FA, Greenberg RN, Berger JR. Neuroimaging correlates of HIV-associated BBB compromise. J Neuroimmunol. 2004;157(1–2):140–146.
  • Newsome SD, Johnson E, Pardo C, McArthur JC, Nath A. Fulminant encephalopathy with basal ganglia hyperintensities in HIV-infected drug users. Neurology. 2011;76(9):787–794.
  • Brinley FJ Jr, Pardo CA, Verma A. Human immunodeficiency virus and the peripheral nervous system workshop. Arch Neurol. 2001;58(10): 1561–1566.
  • Acharjee S, Noorbakhsh F, Stemkowski PL, et al. HIV-1 viral protein R causes peripheral nervous system injury associated with in vivo neuropathic pain. FASEB J. 2010;24(11):4343–4353.
  • Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One. 2010;5(12):e14433.
  • Foster C, Lyall H. HIV and mitochondrial toxicity in children. J Antimicrob Chemother. 2008;61(1):8–12.
  • Van derWatt G. Mitochondrial dysfunction and human immunodeficiency virus infection. JEMDSA. 2011;16(2):94–100.
  • Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1–207.
  • Ferenczy MW, Marshall LJ, Nelson CD, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 2012;25(3):471–506.
  • Nukuzuma S, Nakamichi K, Kameoka M, et al. Efficient propagation of progressive multifocal leukoencephalopathy-type JC virus in COS-7-derived cell lines stably expressing Tat protein of human immunodeficiency virus type 1. Microbiol Immunol. 2010;54(12): 758–762.
  • Stettner MR, Nance JA, Wright CA, et al. SMAD proteins of oligodendroglial cells regulate transcription of JC virus early and late genes coordinately with the Tat protein of human immunodeficiency virus type 1. J Gen Virol. 2009;90(Pt 8):2005–2014.
  • Daniel DC, Wortman MJ, Schiller RJ, et al. Coordinate effects of human immunodeficiency virus type 1 protein Tat and cellular protein Puralpha on DNA replication initiated at the JC virus origin. J Gen Virol. 2001;82(Pt 7):1543–1553.
  • Giudici B, Vaz B, Bossolasco S, et al. Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis. 2000;30(1):95–99.
  • Centers for Disease Control and Prevention. HIV infection among injection-drug users – 34 states, 2004–2007. MMWR Morb Mortal Wkly Rep. 2009;58(46):1291–1295.
  • Vlahov D, Robertson AM, Strathdee SA. Prevention of HIV infection among injection drug users in resource-limited settings. Clin Infect Dis. 2010;50(Suppl 3):S114–S121.
  • Rouveix B. Opiates and immune function. Consequences on infectious diseases with special reference to AIDS. Therapie. 1992;47(6): 503–512.
  • Arora PK. Morphine-induced immune modulation: does it predispose to HIV infection? NIDA Res Monogr. 1990;96:150–165.
  • Bell JE, Brettle RP, Chiswick A, Simmonds P. HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Brain. 1998;121(Pt 11):2043–2052.
  • Bell JE, Arango JC, Robertson R, Brettle RP, Leen C, Simmonds P. HIV and drug misuse in the Edinburgh cohort. J Acquir Immune Defic Syndr. 2002;31(Suppl 2):S35–S42.
  • Arango JC, Simmonds P, Brettle RP, Bell JE. Does drug abuse influence the microglial response in AIDS and HIV encephalitis? AIDS. 2004;18(Suppl 1):S69–S74.
  • Fitting S, Xu R, Bull C, et al. Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol. 2010;177(3):1397–1410.
  • Suzuki M, El-Hage N, Zou S, et al. Fractalkine/CX3CL1 protects striatal neurons from synergistic morphine and HIV-1 Tat-induced dendritic losses and death. Mol Neurodegener. 2011;6:78.
  • Zou S, Fitting S, Hahn YK, et al. Morphine potentiates neurodegenerative effects of HIV-1 Tat through actions at μ;-opioid receptor-expressing glia. Brain. 2011;134(Pt 12):3616–3631.
  • Hauser KF, Hahn YK, Adjan VV, et al. HIV-1 Tat and morphine have interactive effects on oligodendrocyte survival and morphology. Glia. 2009;57(2):194–206.
  • Malik S, Khalique H, Buch S, Seth P. A growth factor attenuates HIV-1 Tat and morphine induced damage to human neurons: implication in HIV/AIDS-drug abuse cases. PLoS One. 2011;6(3):e18116.
  • Khurdayan VK, Buch S, El-Hage N, et al. Preferential vulnerability of astroglia and glial precursors to combined opioid and HIV-1 Tat exposure in vitro. Eur J Neurosci. 2004;19(12):3171–3182.
  • Buch SK, Khurdayan VK, Lutz SE, Knapp PE, El-Hage N, Hauser KF. Glial-restricted precursors: patterns of expression of opioid receptors and relationship to human immunodeficiency virus-1 Tat and morphine susceptibility in vitro. Neuroscience. 2007;146(4):1546–1554.
  • Fitting S, Zou S, Chen W, Vo P, Hauser KF, Knapp PE. Regional heterogeneity and diversity in cytokine and chemokine production by astroglia: differential responses to HIV-1 Tat, gp120, and morphine revealed by multiplex analysis. J Proteome Res. 2010;9(4):1795–1804.
  • Colfax G, Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. Curr HIV/AIDS Rep. 2005;2(4): 194–199.
  • Potula R, Persidsky Y. Adding fuel to the fire: methamphetamine enhances HIV infection. Am J Pathol. 2008;172(6):1467–1470.
  • Liang H, Wang X, Chen H, et al. Methamphetamine enhances HIV infection of macrophages. Am J Pathol. 2008;172(6):1617–1624.
  • Wang X, Wang Y, Ye L, et al. Modulation of intracellular restriction factors contributes to methamphetamine-mediated enhancement of acquired immune deficiency syndrome virus infection of macrophages. Curr HIV Res. 2012;10(5):407–414.
  • Chang L, Ernst T, Speck O, Grob CS. Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychiatry. 2005;162(2):361–369.
  • Degenhardt L, Mathers B, Guarinieri M, et al. Meth/amphetamine use and associated HIV: implications for global policy and public health. Int J Drug Policy. 2010;21(5):347–358.
  • Rippeth JD, Heaton RK, Carey CL, et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc. 2004;10(1):1–14.
  • Pendyala G, Buescher JL, Fox HS. Methamphetamine and inflammatory cytokines increase neuronal Na+/K+-ATPase isoform 3: relevance for HIV associated neurocognitive disorders. PLoS One. 2012;7(5):e37604.
  • Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med. 2002;53:557–593.
  • Nath A, Clements JE. Eradication of HIV from the brain: reasons for pause. AIDS. 2011;25(5):577–580.
  • Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ, Richman DD. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol. 1997;71(3):2059–2071.
  • Zaitseva M, Peden K, Golding H. HIV coreceptors: role of structure, post-translational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors. Biochim Biophys Acta. 2003;1614(1):51–61.
  • Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005;5(1):69–81.
  • Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 coreceptors – central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses. 2004;20(1):111–126.
  • Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R. HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog. 2011;7(10):e1002286.
  • Bagasra O, Lavi E, Bobroski L, et al. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS. 1996;10(6):573–585.
  • Trkola A. HIV-host interactions: vital to the virus and key to its inhibition. Curr Opin Microbiol. 2004;7(4):407–411.
  • Ranki A, Nyberg M, Ovod V, et al. Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with dementia. AIDS. 1995;9(9):1001–1008.
  • Gorry PR, Ong C, Thorpe J, et al. Astrocyte infection by HIV-1: mechanisms of restricted virus replication, and role in the pathogenesis of HIV-1-associated dementia. Curr HIV Res. 2003;1(4):463–473.
  • Ghafouri M, Amini S, Khalili K, Sawaya BE. HIV-1 associated dementia: symptoms and causes. Retrovirology. 2006;3:28.
  • Gorry P, Purcell D, Howard J, McPhee D. Restricted HIV-1 infection of human astrocytes: potential role of nef in the regulation of virus replication. J Neurovirol. 1998;4(4):377–386.
  • Lawrence DM, Durham LC, Schwartz L, Seth P, Maric D, Major EO. Human immunodeficiency virus type 1 infection of human brain-derived progenitor cells. J Virol. 2004;78(14):7319–7328.
  • Oguariri RM, Brann TW, Imamichi T. Hydroxyurea and interleukin-6 synergistically reactivate HIV-1 replication in a latently infected promonocytic cell line via SP1/SP3 transcription factors. J Biol Chem. 2007;282(6):3594–3604.
  • Hoshino S, Konishi M, Mori M, et al. HIV-1 Vpr induces TLR4/ MyD88-mediated IL-6 production and reactivates viral production from latency. J Leukoc Biol. 2010;87(6):1133–1143.
  • Strazza M, Pirrone V, Wigdahl B, Nonnemacher MR. Breaking down the barrier: the effects of HIV-1 on the blood–brain barrier. Brain Res. 2011;1399:96–115.
  • Albright AV, Soldan SS, Gonzalez-Scarano F. Pathogenesis of human immunodeficiency virus-induced neurological disease. J Neurovirol. 2003;9(2):222–227.
  • Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone MB. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A. 1986;83(18):7089–7093.
  • Ward JM, O’Leary TJ, Baskin GB, et al. Immunohistochemical localization of human and simian immunodeficiency viral antigens in fixed tissue sections. Am J Pathol. 1987;127(2):199–205.
  • Wiley CA, Nelson JA. Role of human immunodeficiency virus and cytomegalovirus in AIDS encephalitis. Am J Pathol. 1988;133(1):73–81.
  • Liu NQ, Lossinsky AS, Popik W, et al. Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. J Virol. 2002;76(13):6689–6700.
  • Gras G, Kaul M. Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection. Retrovirology. 2010;7:30.
  • Prospero-Garcia O, Gold LH, Fox HS, et al. Microglia-passaged simian immunodeficiency virus induces neurophysiological abnormalities in monkeys. Proc Natl Acad Sci U S A. 1996;93(24):14158–14163.
  • Kalams SA, Walker BD. Cytotoxic T lymphocytes and HIV-1 related neurologic disorders. Curr Top Microbiol Immunol. 1995;202: 79–88.
  • Mennicken F, Maki R, de Souza EB, Quirion R. Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning. Trends Pharmacol Sci. 1999;20(2):73–78.
  • Mercer J, Helenius A. Virus entry by macropinocytosis. Nat Cell Biol. 2009;11(5):510–520.
  • Dohgu S, Banks WA. Lipopolysaccharide-enhanced transcellular transport of HIV-1 across the blood–brain barrier is mediated by the p38 mitogen-activated protein kinase pathway. Exp Neurol. 2008;210(2):740–749.
  • Stins MF, Pearce D, Di Cello F, Erdreich-Epstein A, Pardo CA, Sik Kim K. Induction of intercellular adhesion molecule-1 on human brain endothelial cells by HIV-1 gp120: role of CD4 and chemokine coreceptors. Lab Invest. 2003;83(12):1787–1798.
  • Toborek M, Lee YW, Flora G, et al. Mechanisms of the blood–brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol. 2005;25(1): 181–199.
  • Malik M, Chen YY, Kienzle MF, Tomkowicz BE, Collman RG, Ptasznik A. Monocyte migration and LFA-1-mediated attachment to brain microvascular endothelia is regulated by SDF-1 alpha through Lyn kinase. J Immunol. 2008;181(7):4632–4637.
  • Williams DW, Eugenin EA, Calderon TM, Berman JW. Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis. J Leukoc Biol. 2012;91(3):401–415.
  • Mayhan WG. Cellular mechanisms by which tumor necrosis factor-α produces disruption of the blood–brain barrier. Brain Res. 2002;927(2): 144–152.
  • Haorah J, Ramirez SH, Floreani N, Gorantla S, Morsey B, Persidsky Y. Mechanism of alcohol-induced oxidative stress and neuronal injury. Free Radic Biol Med. 2008;45(11):1542–1550.
  • Liu Y, Tang XP, McArthur JC, Scott J, Gartner S. Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. J Neurovirol. 2000;6(Suppl 1):S70–S81.
  • Izquierdo-Useros N, Naranjo-Gomez M, Erkizia I, et al. HIV and mature dendritic cells: Trojan exosomes riding the Trojan horse? PLoS Pathog. 2010;6(3):e1000740.
  • Peluso R, Haase A, Stowring L, Edwards M, Ventura P. A Trojan horse mechanism for the spread of visna virus in monocytes. Virology. 1985;147(1):231–236.
  • Georgsson G. Neuropathologic aspects of lentiviral infections. Ann N Y Acad Sci. 1994;724:50–67.
  • Romero IA, Prevost MC, Perret E, et al. Interactions between brain endothelial cells and human T-cell leukemia virus type 1-infected lymphocytes: mechanisms of viral entry into the central nervous system. J Virol. 2000;74(13):6021–6030.
  • Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P. HIV-1 infection and cognitive impairment in the cART era: a review. AIDS. 2011;25(5): 561–575.
  • Gartner S. HIV infection and dementia. Science. 2000;287(5453): 602–604.
  • Zheng J, Thylin MR, Persidsky Y, et al. HIV-1 infected immune competent mononuclear phagocytes influence the pathways to neuronal demise. Neurotox Res. 2001;3(5):461–484.
  • Adamson DC, Kopnisky KL, Dawson TM, Dawson VL. Mechanisms and structural determinants of HIV-1 coat protein, gp41-induced neurotoxicity. J Neurosci. 1999;19(1):64–71.
  • Johnston JB, Zhang K, Silva C, et al. HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Ann Neurol. 2001;49(2):230–241.
  • Wallace DR. HIV neurotoxicity: potential therapeutic interventions. J Biomed Biotechnol. 2006;2006(3):1–10.
  • Hult B, Chana G, Masliah E, Everall I. Neurobiology of HIV. Int Rev Psychiatry. 2008;20(1):3–13.
  • Kanmogne GD, Kennedy RC, Grammas P. HIV-1 gp120 proteins and gp160 peptides are toxic to brain endothelial cells and neurons: possible pathway for HIV entry into the brain and HIV-associated dementia. J Neuropathol Exp Neurol. 2002;61(11):992–1000.
  • Hesselgesser J, Halks-Miller M, DelVecchio V, et al. CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons. Curr Biol. 1997;7(2):112–121.
  • Cao S, Wu C, Yang Y, et al. Lentiviral vector-mediated stable expression of sTNFR-Fc in human macrophage and neuronal cells as a potential therapy for neuro AIDS. J Neuroinflammation. 2011;8:48.
  • Zheng J, Thylin MR, Ghorpade A, et al. Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia. J Neuroimmunol. 1999;98(2):185–200.
  • Meucci O, Fatatis A, Simen AA, Miller RJ. Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc Natl Acad Sci U S A. 2000;97(14):8075–8080.
  • Chen L, Liu J, Xu C, Keblesh J, Zang W, Xiong H. HIV-1 gp120 induces neuronal apoptosis through enhancement of 4-aminopyridine-senstive outward K+ currents. PLoS One. 2011;6(10):e25994.
  • Fontana G, Valenti L, Raiteri M. Gp120 can revert antagonism at the glycine site of NMDA receptors mediating GABA release from cultured hippocampal neurons. J Neurosci Res. 1997;49(6):732–738.
  • Chen W, Tang Z, Fortina P, et al. Ethanol potentiates HIV-1 gp120-induced apoptosis in human neurons via both the death receptor and NMDA receptor pathways. Virology. 2005;334(1):59–73.
  • Brown GC, Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol. 2003;27(3): 325–355.
  • Liu Y, Jones M, Hingtgen CM, et al. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat Med. 2000;6(12):1380–1387.
  • Nath A, Haughey NJ, Jones M, Anderson C, Bell JE, Geiger JD. Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann Neurol. 2000;47(2): 186–194.
  • Prendergast MA, Rogers DT, Mulholland PJ, et al. Neurotoxic effects of the human immunodeficiency virus type-1 transcription factor Tat require function of a polyamine sensitive-site on the N-methyl-D-aspartate receptor. Brain Res. 2002;954(2):300–307.
  • Smith DG, Guillemin GJ, Pemberton L, et al. Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. J Neurovirol. 2001;7(1):56–60.
  • Jones GJ, Barsby NL, Cohen EA, et al. HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci. 2007;27(14): 3703–3711.
  • Piller SC, Jans P, Gage PW, Jans DA. Extracellular HIV-1 virus protein R causes a large inward current and cell death in cultured hippocampal neurons: implications for AIDS pathology. Proc Natl Acad Sci U S A. 1998;95(8):4595–4600.
  • Kaul M, Lipton SA. Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr HIV Res. 2006;4(3):307–318.
  • Lisi L, Tramutola A, De Luca A, Navarra P, Dello Russo C. Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120. J Neurochem. 2012;120(1):106–114.
  • Agrawal L, Louboutin JP, Reyes BA, Van Bockstaele EJ, Strayer DS. HIV-1 Tat neurotoxicity: a model of acute and chronic exposure, and neuroprotection by gene delivery of antioxidant enzymes. Neurobiol Dis. 2012;45(2):657–670.
  • Bezzi P, Domercq M, Brambilla L, et al. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci. 2001;4(7):702–710.
  • Yang Y, Yao H, Lu Y, Wang C, Buch S. Cocaine potentiates astrocyte toxicity mediated by human immunodeficiency virus (HIV-1) protein gp120. PLoS One. 2010;5(10):e13427.
  • Nath A, Conant K, Chen P, Scott C, Major EO. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J Biol Chem. 1999;274(24): 17098–17102.
  • Dugas N, Lacroix C, Kilchherr E, Delfraissy JF, Tardieu M. Role of CD23 in astrocytes inflammatory reaction during HIV-1 related encephalitis. Cytokine. 2001;15(2):96–107.
  • Gorry PR, Taylor J, Holm GH, et al. Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol. 2002;76(12): 6277–6292.
  • Kaul M, Ma Q, Medders KE, Desai MK, Lipton SA. HIV-1 coreceptors CCR5 and CXCR4 both mediate neuronal cell death but CCR5 paradoxically can also contribute to protection. Cell Death Differ. 2007;14(2):296–305.
  • Scaravilli F, Bazille C, Gray F. Neuropathologic contributions to understanding AIDS and the central nervous system. Brain Pathol. 2007;17(2):197–208.
  • Lawrence DM, Major EO. HIV-1 and the brain: connections between HIV-1-associated dementia, neuropathology and neuroimmunology. Microbes Infect. 2002;4(3):301–308.
  • Glass JD, Fedor H, Wesselingh SL, McArthur JC. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol. 1995;38(5):755–762.
  • Masliah E, Heaton RK, Marcotte TD, et al; HIV Neurobehavioral Research Center. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. 1997;42(6): 963–972.
  • Xu J, Ikezu T. The comorbidity of HIV-associated neurocognitive disorders and Alzheimer’s disease: a foreseeable medical challenge in post-HAART era. J Neuroimmune Pharmacol. 2009;4(2):200–212.
  • Cook-Easterwood J, Middaugh LD, Griffin WC 3rd, Khan I, Tyor WR. Highly active antiretroviral therapy of cognitive dysfunction and neuronal abnormalities in SCID mice with HIV encephalitis. Exp Neurol. 2007;205(2):506–512.
  • Rostasy K, Monti L, Lipton SA, Hedreen JC, Gonzalez RG, Navia BA. HIV leucoencephalopathy and TNFalpha expression in neurones. J Neurol Neurosurg Psychiatry. 2005;76(7):960–964.
  • Ownby RL, Kumar AM, Benny Fernandez J, et al. Tumor necrosis factor-alpha levels in HIV-1 seropositive injecting drug users. J Neuroimmune Pharmacol. 2009;4(3):350–358.
  • Airoldi M, Bandera A, Trabattoni D, et al. Neurocognitive impairment in HIV-infected naive patients with advanced disease: the role of virus and intrathecal immune activation. Clin Dev Immunol. 2012;2012:467154.
  • Jiang ZG, Piggee C, Heyes MP, et al. Glutamate is a mediator of neurotoxicity in secretions of activated HIV-1-infected macrophages. J Neuroimmunol. 2001;117(1–2):97–107.
  • Kandanearatchi A, Brew BJ. The kynurenine pathway and quinolinic acid: pivotal roles in HIV associated neurocognitive disorders. FEBS J. 2012;279(8):1366–1374.
  • Gelman BB, Nguyen TP. Synaptic proteins linked to HIV-1 infection and immunoproteasome induction: proteomic analysis of human synaptosomes. J Neuroimmune Pharmacol. 2010;5(1):92–102.
  • Lu SM, Tremblay ME, King IL, et al. HIV-1 Tat-induced microgliosis and synaptic damage via interactions between peripheral and central myeloid cells. PLoS One. 2011;6(9):e23915.
  • Fox L, Alford M, Achim C, Mallory M, Masliah E. Neurodegeneration of somatostatin-immunoreactive neurons in HIV encephalitis. J Neuropathol Exp Neurol. 1997;56(4):360–368.
  • Harezlak J, Buchthal S, Taylor M, et al. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS. 2011;25(5): 625–633.
  • Adle-Biassette H, Levy Y, Colombel M, et al. Neuronal apoptosis in HIV infection in adults. Neuropathol Appl Neurobiol. 1995;21(3): 218–227.
  • Gelbard HA, James HJ, Sharer LR, et al. Apoptotic neurons in brains from paediatric patients with HIV-1 encephalitis and progressive encephalopathy. Neuropathol Appl Neurobiol. 1995;21(3): 208–217.
  • Petito CK, Roberts B. Evidence of apoptotic cell death in HIV encephalitis. Am J Pathol. 1995;146(5):1121–1130.
  • Adle-Biassette H, Chretien F, Wingertsmann L, et al. Neuronal apoptosis does not correlate with dementia in HIV infection but is related to microglial activation and axonal damage. Neuropathol Appl Neurobiol. 1999;25(2):123–133.
  • Tyor WR, Wesselingh SL, Griffin JW, McArthur JC, Griffin DE. Unifying hypothesis for the pathogenesis of HIV-associated dementia complex, vacuolar myelopathy, and sensory neuropathy. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9(4):379–388.
  • Xing HQ, Moritoyo T, Mori K, Sugimoto C, Ono F, Izumo S. Expression of proinflammatory cytokines and its relationship with virus infection in the brain of macaques inoculated with macrophage-tropic simian immunodeficiency virus. Neuropathology. 2009;29(1): 13–19.
  • Salomoni P, Cossarizza A. HIV: no PUMA no death? Cell Death Differ. 2004;11(7):691–692.
  • Bissel SJ, Wang G, Bonneh-Barkay D, et al. Systemic and brain macrophage infections in relation to the development of simian immunodeficiency virus encephalitis. J Virol. 2008;82(10): 5031–5042.
  • Yadav A, Collman RG. CNS inflammation and macrophage/microglial biology associated with HIV-1 infection. J Neuroimmune Pharmacol. 2009;4(4):430–447.
  • Valcour VG, Shiramizu BT, Shikuma CM. HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications. J Leukoc Biol. 2010;87(4):621–626.
  • Rumbaugh JA, Nath A. Developments in HIV neuropathogenesis. Curr Pharm Des. 2006;12(9):1023–1044.
  • Vallat-Decouvelaere AV, Chretien F, Gras G, Le Pavec G, Dormont D, Gray F. Expression of excitatory amino acid transporter-1 in brain macrophages and microglia of HIV-infected patients. A neuroprotective role for activated microglia? J Neuropathol Exp Neurol. 2003;62(5): 475–485.
  • Gras G, Chretien F, Vallat-Decouvelaere AV, et al. Regulated expression of sodium-dependent glutamate transporters and synthetase: a neuroprotective role for activated microglia and macrophages in HIV infection? Brain Pathol. 2003;13(2):211–222.
  • Sippy BD, Hofman FM, Wallach D, Hinton DR. Increased expression of tumor necrosis factor-alpha receptors in the brains of patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10(5): 511–521.
  • Tyor WR, Glass JD, Griffin JW, et al. Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann Neurol. 1992;31(4):349–360.
  • Turchan-Cholewo J, Dimayuga VM, Gupta S, Gorospe RM, Keller JN, Bruce-Keller AJ. NADPH oxidase drives cytokine and neurotoxin release from microglia and macrophages in response to HIV-Tat. Antioxid Redox Signal. 2009;11(2):193–204.
  • Pais TF, Figueiredo C, Peixoto R, Braz MH, Chatterjee S. Necrotic neurons enhance microglial neurotoxicity through induction of glutaminase by a MyD88-dependent pathway. J Neuroinflammation. 2008;5:43.
  • Robinson AP, White TM, Mason DW. Macrophage heterogeneity in the rat as delineated by two monoclonal antibodies MRC OX-41 and MRC OX-42, the latter recognizing complement receptor type 3. Immunology. 1986;57(2):239–247.
  • Miwa T, Furukawa S, Nakajima K, Furukawa Y, Kohsaka S. Lipopolysaccharide enhances synthesis of brain-derived neurotrophic factor in cultured rat microglia. J Neurosci Res. 1997;50(6): 1023–1029.
  • Nicholas RS, Stevens S, Wing MG, Compston DA. Microglia-derived IGF-2 prevents TNFalpha induced death of mature oligodendrocytes in vitro. J Neuroimmunol. 2002;124(1–2):36–44.
  • Garaci E, Caroleo MC, Aloe L, et al. Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV. Proc Natl Acad Sci U S A. 1999;96(24):14013–14018.
  • Chao CC, Hu S, Sheng WS, Peterson PK. Tumor necrosis factor-alpha production by human fetal microglial cells: regulation by other cytokines. Dev Neurosci. 1995;17(2):97–105.
  • Kullander K, Kylberg A, Ebendal T. Specificity of neurotrophin-3 determined by loss-of-function mutagenesis. J Neurosci Res. 1997;50(3):496–503.
  • Batchelor PE, Liberatore GT, Wong JY, et al. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci. 1999;19(5): 1708–1716.
  • Kerschensteiner M, Gallmeier E, Behrens L, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med. 1999;189(5):865–870.
  • Ziemssen T, Kumpfel T, Klinkert WE, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain. 2002;125(Pt 11):2381–2391.
  • Chen M, Valenzuela RM, Dhib-Jalbut S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci. 2003;215(1–2):37–44.
  • Kuo HS, Tsai MJ, Huang MC, et al. Acid fibroblast growth factor and peripheral nerve grafts regulate Th2 cytokine expression, macrophage activation, polyamine synthesis, and neurotrophin expression in transected rat spinal cords. J Neurosci. 2011;31(11): 4137–4147.
  • Lisak RP, Benjamins JA, Bealmear B, et al. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for glial and neural-related molecules in central nervous system mixed glial cell cultures: neurotrophins, growth factors and structural proteins. J Neuroinflammation. 2007;4:30.
  • Benner EJ, Mosley RL, Destache CJ, et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson’s disease. Proc Natl Acad Sci U S A. 2004;101(25):9435–9440.
  • Chertoff M, Di Paolo N, Schoeneberg A, et al. Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor α in the nigrostriatal dopaminergic circuit of adult mice. Exp Neurol. 2011;227(2):237–251.
  • Dolga AM, Granic I, Blank T, et al. TNF-alpha-mediates neuroprotection against glutamate-induced excitotoxicity via NF-kappaB-dependent up-regulation of K2. 2 channels. J Neurochem. 2008;107(4):1158–1167.
  • Turrin NP, Rivest S. Tumor necrosis factor α but not interleukin 1β mediates neuroprotection in response to acute nitric oxide excitotoxicity. J Neurosci. 2006;26(1):143–151.
  • Orellana DI, Quintanilla RA, Maccioni RB. Neuroprotective effect of TNFalpha against the beta-amyloid neurotoxicity mediated by CDK5 kinase. Biochim Biophys Acta. 2007;1773(2):254–263.
  • Fine SM, Angel RA, Perry SW, et al. Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia. J Biol Chem. 1996;271(26):15303–15306.
  • Zou JY, Crews FT. TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res. 2005;1034(1–2): 11–24.
  • Nakaizumi A, Horie T, Kida T, et al. Nitric oxide potentiates TNF-α-induced neurotoxicity through suppression of NF-κB. Cell Mol Neurobiol. 2012;32(1):95–106.
  • Williams R, Yao H, Dhillon NK, Buch SJ. HIV-1 Tat co-operates with IFN-gamma and TNF-alpha to increase CXCL10 in human astrocytes. PLoS One. 2009;4(5):e5709.
  • Matzen K, Dirkx AE, oude Egbrink MG, et al. HIV-1 Tat increases the adhesion of monocytes and T-cells to the endothelium in vitro and in vivo: implications for AIDS-associated vasculopathy. Virus Res. 2004;104(2):145–155.
  • Jiang J, Fu W, Wang X, Lin PH, Yao Q, Chen C. HIV gp120 induces endothelial dysfunction in tumour necrosis factor-alpha-activated porcine and human endothelial cells. Cardiovasc Res. 2010;87(2): 366–374.
  • Brabers NA, Nottet HS. Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia. Eur J Clin Invest. 2006;36(7):447–458.
  • Kfutwah AK, Mary JY, Nicola MA, et al. Tumour necrosis factor-alpha stimulates HIV-1 replication in single-cycle infection of human term placental villi fragments in a time, viral dose and envelope dependent manner. Retrovirology. 2006;3:36.
  • Haraguchi S, Day NK, Kamchaisatian W, et al. LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells. AIDS Res Ther. 2006;3:8.
  • Boven LA, Vergnolle N, Henry SD, et al. Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis. J Immunol. 2003;170(5):2638–2646.
  • Anderson CE, Tomlinson GS, Pauly B, et al. Relationship of Nefpositive and GFAP-reactive astrocytes to drug use in early and late HIV infection. Neuropathol Appl Neurobiol. 2003;29(4):378–388.
  • Chauhan A, Hahn S, Gartner S, et al. Molecular programming of endothelin-1 in HIV-infected brain: role of Tat in up-regulation of ET-1 and its inhibition by statins. FASEB J. 2007;21(3): 777–789.
  • Croitoru-Lamoury J, Guillemin GJ, Boussin FD, et al. Expression of chemokines and their receptors in human and simian astrocytes: evidence for a central role of TNF alpha and IFN gamma in CXCR4 and CCR5 modulation. Glia. 2003;41(4):354–370.
  • Ronaldson PT, Bendayan R. HIV-1 viral envelope glycoprotein gp120 triggers an inflammatory response in cultured rat astrocytes and regulates the functional expression of P-glycoprotein. Mol Pharmacol. 2006;70(3):1087–1098.
  • Schweighardt B, Atwood WJ. HIV type 1 infection of human astrocytes is restricted by inefficient viral entry. AIDS Res Hum Retroviruses. 2001;17(12):1133–1142.
  • Liu Y, Liu H, Kim BO, et al. CD4-independent infection of astrocytes by human immunodeficiency virus type 1: requirement for the human mannose receptor. J Virol. 2004;78(8):4120–4133.
  • Chen P, Mayne M, Power C, Nath A. The Tat protein of HIV-1 induces tumor necrosis factor-alpha production: implications for HIV-1-associated neurological diseases. J Biol Chem. 1997;272(36): 22385–22388.
  • Mollace V, Salvemini D, Riley DP, et al. The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages. J Leukoc Biol. 2002;71(1):65–72.
  • Zhang K, McQuibban GA, Silva C, et al. HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat Neurosci. 2003;6(10):1064–1071.
  • Rappaport J, Joseph J, Croul S, et al. Molecular pathway involved in HIV-1-induced CNS pathology: role of viral regulatory protein, Tat. J Leukoc Biol. 1999;65(4):458–465.
  • Nath A. Human immunodeficiency virus-associated neurocognitive disorder: pathophysiology in relation to drug addiction. Ann N Y Acad Sci. 2010;1187:122–128.
  • Li J, Bentsman G, Potash MJ, Volsky DJ. Human immunodeficiency virus type 1 efficiently binds to human fetal astrocytes and induces neuroinflammatory responses independent of infection. BMC Neurosci. 2007;8:31.
  • Khan NA, Di Cello F, Nath A, Kim KS. Human immunodeficiency virus type 1 tat-mediated cytotoxicity of human brain microvascular endothelial cells. J Neurovirol. 2003;9(6):584–593.
  • Kim TA, Avraham HK, Koh YH, Jiang S, Park IW, Avraham S. HIV-1 Tat-mediated apoptosis in human brain microvascular endothelial cells. J Immunol. 2003;170(5):2629–2637.
  • Ullrich CK, Groopman JE, Ganju RK. HIV-1 gp120- and gp160-induced apoptosis in cultured endothelial cells is mediated by caspases. Blood. 2000;96(4):1438–1442.
  • Park IW, Ullrich CK, Schoenberger E, Ganju RK, Groopman JE. HIV-1 Tat induces microvascular endothelial apoptosis through caspase activation. J Immunol. 2001;167(5):2766–2771.
  • Price TO, Uras F, Banks WA, Ercal N. A novel antioxidant N-acetylcysteine amide prevents gp120- and Tat-induced oxidative stress in brain endothelial cells. Exp Neurol. 2006;201(1):193–202.
  • Acheampong EA, Parveen Z, Muthoga LW, Kalayeh M, Mukhtar M, Pomerantz RJ. Human immunodeficiency virus type 1 Nef potently induces apoptosis in primary human brain microvascular endothelial cells via the activation of caspases. J Virol. 2005;79(7):4257–4269.
  • Ren Z, Yao Q, Chen C. HIV-1 envelope glycoprotein 120 increases intercellular adhesion molecule-1 expression by human endothelial cells. Lab Invest. 2002;82(3):245–255.
  • Pieper GM, Olds CL, Bub JD, Lindholm PF. Transfection of human endothelial cells with HIV-1 tat gene activates NF-kappa B and enhances monocyte adhesion. Am J Physiol Heart Circ Physiol. 2002;283(6):H2315–H2321.
  • Andras IE, Pu H, Deli MA, Nath A, Hennig B, Toborek M. HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J Neurosci Res. 2003;74(2): 255–265.
  • Price TO, Ercal N, Nakaoke R, Banks WA. HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells. Brain Res. 2005;1045(1–2):57–63.
  • Lu TS, Avraham HK, Seng S, et al. Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells. J Immunol. 2008;181(9):6406–6416.
  • Afonso PV, Ozden S, Cumont MC, et al. Alteration of blood–brain barrier integrity by retroviral infection. PLoS Pathog. 2008;4(11): e1000205.
  • Enting RH, Hoetelmans RM, Lange JM, Burger DM, Beijnen JH, Portegies P. Antiretroviral drugs and the central nervous system. AIDS. 1998;12(15):1941–1955.
  • Karkan D, Pfeifer C, Vitalis TZ, et al. A unique carrier for delivery of therapeutic compounds beyond the blood–brain barrier. PLoS One. 2008;3(6):e2469.
  • Bennewitz MF, Saltzman WM. Nanotechnology for delivery of drugs to the brain for epilepsy. Neurotherapeutics. 2009;6(2):323–336.
  • Liu S, Levine SR, Winn HR. Targeting ischemic penumbra. Part II: selective drug delivery using liposome technologies. J Exp Stroke Transl Med. 2011;4(1):16–23.
  • Simpson DM, Elliott KJ, McArthur J. Peripheral neuropathy. In: Gendelman HE, Grant I, Everall IP, et al, editors. The Neurology of AIDS. 3rd ed. New York, NY: Oxford University Press; 2012: 536–546.
  • Wasti SP, Simkhada P, Randall J, van Teijlingen E. Issues and challenges of HIV/AIDS prevention and treatment programme in Nepal. Glob J Health Sci. 2009;1(2):62–72.
  • Selwyn PA, Rivard M. Palliative care for AIDS: challenges and opportunities in the era of highly active anti-retroviral therapy. J Palliat Med. 2003;6(3):475–487.
  • Shehu-Xhilaga M, Tachedjian G, Crowe SM, Kedzierska K. Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1. Curr Med Chem. 2005;12(15):1705–1719.
  • Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010;50(5):773–778.
  • AIDSinfo; United States Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 14, 2011. Available from: http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed August 16, 2012.
  • Ene L, Duiculescu D, Ruta SM. How much do antiretroviral drugs penetrate into the central nervous system? J Med Life. 2011;4(4): 432–439.
  • Brew BJ. Benefit or toxicity from neurologically targeted antiretroviral therapy? Clin Infect Dis. 2010;50(6):930–932.
  • Han RZ, Hu JJ, Weng YC, Li DF, Huang Y. NMDA receptor antagonist MK-801 reduces neuronal damage and preserves learning and memory in a rat model of traumatic brain injury. Neurosci Bull. 2009;25(6):367–375.
  • Toggas SM, Masliah E, Mucke L. Prevention of HIV-1 gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine. Brain Res. 1996;706(2): 303–307.
  • Lipton SA. Erythropoietin for neurologic protection and diabetic neuropathy. N Engl J Med. 2004;350(24):2516–2517.
  • Alisky JM. Could cholinesterase inhibitors and memantine alleviate HIV dementia? J Acquir Immune Defic Syndr. 2005;38(1): 113–114.
  • Anderson ER, Gendelman HE, Xiong H. Memantine protects hippocampal neuronal function in murine human immunodeficiency virus type 1 encephalitis. J Neurosci. 2004;24(32):7194–7198.
  • Xia P, Chen HS, Zhang D, Lipton SA. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci. 2010;30(33):11246–11250.
  • Schifitto G, Navia BA, Yiannoutsos CT, et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007;21(14): 1877–1886.
  • Doody R, Wirth Y, Schmitt F, Mobius HJ. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer’s disease. Dement Geriatr Cogn Disord. 2004;18(2):227–232.
  • Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348(14):1333–1341.
  • Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14(2):135–146.
  • Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzheimer’s disease: tolerability and safety data from clinical trials. Drug Saf. 2008;31(7):577–585.
  • Kavirajan H. Memantine: a comprehensive review of safety and efficacy. Expert Opin Drug Saf. 2009;8(1):89–109.
  • de Carvalho M, Pinto S, Costa J, Evangelista T, Ohana B, Pinto A. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11(5):456–460.
  • Zhao Y, Navia BA, Marra CM, et al. Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials. 2010;11(1): 59–67.
  • Turchan J, Sacktor N, Wojna V, Conant K, Nath A. Neuroprotective therapy for HIV dementia. Curr HIV Res. 2003;1(4):373–383.
  • Schifitto G, Sacktor N, Marder K, et al; Neurological AIDS Research Consortium. Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurology. 1999;53(2):391–396.
  • Navia BA, Dafni U, Simpson D, et al. A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology. 1998;51(1): 221–228.
  • Deng Y, Fang W, Li Y, et al. Blood–brain barrier breakdown by PAF and protection by XQ-1H due to antagonism of PAF effects. Eur J Pharmacol. 2009;616(1–3):43–47.
  • van Patot MC, Keyes LE, Leadbetter G 3rd, Hackett PH. Ginkgo biloba for prevention of acute mountain sickness: does it work? High Alt Med Biol. 2009;10(1):33–43.
  • Dube B, Benton T, Cruess DG, Evans DL. Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci. 2005;30(4):237–246.
  • Heseltine PN, Goodkin K, Atkinson JH, et al. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol. 1998;55(1):41–51.
  • Clifford DB, McArthur JC, Schifitto G, et al. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology. 2002;59(10):1568–1573.
  • The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. Neurology. 1997;49(1):142–146.
  • The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Neurology. 1998;50(3):645–651.
  • Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, Kieburtz K. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology. 2000;54(1): 233–235.
  • Schifitto G, Zhang J, Evans SR, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology. 2007;69(13):1314–1321.
  • Schifitto G, Yiannoutsos CT, Ernst T, et al. Selegiline and oxidative stress in HIV-associated cognitive impairment. Neurology. 2009;73(23):1975–1981.
  • Letendre SL, Woods SP, Ellis RJ, et al. Lithium improves HIV-associated neurocognitive impairment. AIDS. 2006;20(14):1885–1888.
  • Schifitto G, Zhong J, Gill D, et al. Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol. 2009;15(2):176–186.
  • Sacktor N, Miyahara S, Deng L, et al. Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology. 2011;77(12):1135–1142.
  • Schifitto G, Peterson DR, Zhong J, et al. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology. 2006;66(6):919–921.
  • Dou H, Kingsley JD, Mosley RL, Gelbard HA, Gendelman HE. Neuroprotective strategies for HIV-1 associated dementia. Neurotox Res. 2004;6(7–8):503–521.
  • Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem. 1999;72(3):1327–1330.
  • Li D, August S, Woulfe DS. GSK3beta is a negative regulator of platelet function and thrombosis. Blood. 2008;111(7):3522–3530.
  • Barry FA, Graham GJ, Fry MJ, Gibbins JM. Regulation of glycogen synthase kinase 3 in human platelets: a possible role in platelet function? FEBS Lett. 2003;553(1–2):173–178.
  • Maggirwar SB, Tong N, Ramirez S, Gelbard HA, Dewhurst S. HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. J Neurochem. 1999;73(2):578–586.
  • Gelbard HA, Nottet HS, Swindells S, et al. Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin. J Virol. 1994;68(7):4628–4635.
  • Hall AC, Brennan A, Goold RG, et al. Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol Cell Neurosci. 2002;20(2):257–270.
  • Koivisto L, Alavian K, Hakkinen L, Pelech S, McCulloch CA, Larjava H. Glycogen synthase kinase-3 regulates formation of long lamellipodia in human keratinocytes. J Cell Sci. 2003;116(Pt 18): 3749–3760.
  • Chen S, Hillman DE. Immunohistochemical localization of protein kinase C delta during postnatal development of the cerebellum. Brain Res Dev Brain Res. 1994;80(1–2):19–25.
  • Manji HK, McNamara R, Chen G, Lenox RH. Signalling pathways in the brain: cellular transduction of mood stabilisation in the treatment of manic-depressive illness. Aust N Z J Psychiatry. 1999;33(Suppl): S65–S83.
  • Lenox RH, McNamara RK, Watterson JM, Watson DG. Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? J Clin Psychiatry. 1996;57(Suppl 13):S23–S31.
  • Cysique LA, Maruff P, Brew BJ. Valproic acid is associated with cognitive decline in HIV-infected individuals: a clinical observational study. BMC Neurol. 2006;6:42.
  • Spera PA, Ellison JA, Feuerstein GZ, Barone FC. IL-10 reduces rat brain injury following focal stroke. Neurosci Lett. 1998;251(3): 189–192.
  • Abraham KE, McMillen D, Brewer KL. The effects of endogenous interleukin-10 on gray matter damage and the development of pain behaviors following excitotoxic spinal cord injury in the mouse. Neuroscience. 2004;124(4):945–952.
  • Dietrich WD, Busto R, Bethea JR. Postischemic hypothermia and IL-10 treatment provide long-lasting neuroprotection of CA1 hippocampus following transient global ischemia in rats. Exp Neurol. 1999;158(2):444–450.
  • Sholl-Franco A, Marques PM, Ferreira CM, de Araujo EG. IL-4 increases GABAergic phenotype in rat retinal cell cultures: involvement of muscarinic receptors and protein kinase C. J Neuroimmunol. 2002;133(1–2):20–29.
  • Huang P, Zhang SS, Zhang C. Erratum: the two sides of cytokine signaling and glaucomatous optic neuropathy. J Ocul Biol Dis Infor. 2009;2(3):98–103.
  • Digicaylioglu M, Garden G, Timberlake S, Fletcher L, Lipton SA. Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc Natl Acad Sci U S A. 2004;101(26):9855–9860.
  • Kim I, Kim CH, Yim YS, Ahn YS. Autocrine function of erythropoietin in IGF-1-induced erythropoietin biosynthesis. Neuroreport. 2008;19(17):1699–1703.
  • Wu C, Cao S, Maggirwar S, Dewhurst S, Lu Y. Construction and characterization of lentiviral vector-mediated expression of TNFR as a potential protective molecule in human neuronal cells [abstract]. J Neuroimmune Pharmacol. 2012;7(Suppl 1):S60.
  • Bruno V, Copani A, Besong G, Scoto G, Nicoletti F. Neuroprotective activity of chemokines against N-methyl-D-aspartate or beta-amyloidinduced toxicity in culture. Eur J Pharmacol. 2000;399(2–3): 117–121.
  • Cook A, Hippensteel R, Shimizu S, Nicolai J, Fatatis A, Meucci O. Interactions between chemokines: regulation of fractalkine/CX3CL1 homeostasis by SDF/CXCL12 in cortical neurons. J Biol Chem. 2010;285(14):10563–10571.
  • Kaul M, Lipton SA. Signaling pathways to neuronal damage and apoptosis in human immunodeficiency virus type 1-associated dementia: chemokine receptors, excitotoxicity, and beyond. J Neurovirol. 2004;10(Suppl 1):97–101.
  • Connor B, Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res Brain Res Rev. 1998;27(1):1–39.
  • Moalem G, Gdalyahu A, Shani Y, et al. Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. J Autoimmun. 2000;15(3):331–345.
  • Dou H, Birusingh K, Faraci J, et al. Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci. 2003;23(27):9162–9170.
  • Paula-Barbosa MM, Pereira PA, Cadete-Leite A, Dulce Madeira M. NGF and NT-3 exert differential effects on the expression of neuropeptides in the suprachiasmatic nucleus of rats withdrawn from ethanol treatment. Brain Res. 2003;983(1–2):64–73.
  • Meeker RB, Poulton W, Feng WH, Hudson L, Longo FM. Suppression of immunodeficiency virus-associated neural damage by the p75 neurotrophin receptor ligand, LM11A-31, in an in vitro feline model. J Neuroimmune Pharmacol. 2012;7(2):388–400.
  • Chauhan NB, Siegel GJ, Lee JM. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson’s disease brain. J Chem Neuroanat. 2001;21(4):277–288.
  • Felderhoff-Mueser U, Sifringer M, Pesditschek S, et al. Pathways leading to apoptotic neurodegeneration following trauma to the developing rat brain. Neurobiol Dis. 2002;11(2):231–245.
  • Johnson VJ, Sharma RP. Aluminum disrupts the pro-inflammatory cytokine/neurotrophin balance in primary brain rotation-mediated aggregate cultures: possible role in neurodegeneration. Neurotoxicology. 2003;24(2):261–268.
  • Meucci O, Miller RJ. Gp120-induced neurotoxicity in hippocampal pyramidal neuron cultures: protective action of TGF-beta1. J Neurosci. 1996;16(13):4080–4088.
  • Ramirez SH, Sanchez JF, Dimitri CA, Gelbard HA, Dewhurst S, Maggirwar SB. Neurotrophins prevent HIV Tat-induced neuronal apoptosis via a nuclear factor-kappaB (NF-kappaB)-dependent mechanism. J Neurochem. 2001;78(4):874–889.
  • Titanji K, Nilsson A, Morch C, et al. Low frequency of plasma nerve-growth factor detection is associated with death of memory B lymphocytes in HIV-1 infection. Clin Exp Immunol. 2003;132(2):297–303.
  • Bachis A, Major EO, Mocchetti I. Brain-derived neurotrophic factor inhibits human immunodeficiency virus-1/gp120-mediated cerebellar granule cell death by preventing gp120 internalization. J Neurosci. 2003;23(13):5715–5722.
  • Mocchetti I, Nosheny RL, Tanda G, Ren K, Meyer EM. Brain-derived neurotrophic factor prevents human immunodeficiency virus type 1 protein gp120 neurotoxicity in the rat nigrostriatal system. Ann N Y Acad Sci. 2007;1122:144–154.
  • Everall IP, Trillo-Pazos G, Bell C, Mallory M, Sanders V, Masliah E. Amelioration of neurotoxic effects of HIV envelope protein gp120 by fibroblast growth factor: a strategy for neuroprotection. J Neuropathol Exp Neurol. 2001;60(3):293–301.
  • Zou CG, Cao XZ, Zhao YS, et al. The molecular mechanism of endoplasmic reticulum stress-induced apoptosis in PC-12 neuronal cells: the protective effect of insulin-like growth factor I. Endocrinology. 2009;150(1):277–285.
  • Poser S, Impey S, Xia Z, Storm DR. Brain-derived neurotrophic factor protection of cortical neurons from serum withdrawal-induced apoptosis is inhibited by cAMP. J Neurosci. 2003;23(11):4420–4427.
  • Hellman M, Arumae U, Yu LY, et al. Mesencephalic astrocyte-derived neurotrophic factor (MANF) has a unique mechanism to rescue apoptotic neurons. J Biol Chem. 2011;286(4):2675–2680.
  • Zhang J, Shi Q, Chen X, et al. Retroviral vector-mediated hypoxia-regulated neurotrophin-3 gene transfer reduces apoptosis induced by hypoxia in PC12 cells. Mol Neurodegener. 2012;7(Suppl 1):S17.
  • Nguyen N, Lee SB, Lee YS, Lee KH, Ahn JY. Neuroprotection by NGF and BDNF against neurotoxin-exerted apoptotic death in neural stem cells are mediated through Trk receptors, activating PI3-kinase and MAPK pathways. Neurochem Res. 2009;34(5):942–951.
  • Yuan J, Yankner BA. Apoptosis in the nervous system. Nature. 2000;407(6805):802–809.
  • Cid C, Alvarez-Cermeno JC, Regidor I, Plaza J, Salinas M, Alcazar A. Caspase inhibitors protect against neuronal apoptosis induced by cerebrospinal fluid from multiple sclerosis patients. J Neuroimmunol. 2003;136(1–2):119–124.
  • Hanko E, Hansen TW, Almaas R, Paulsen R, Rootwelt T. Synergistic protection of a general caspase inhibitor and MK-801 in bilirubininduced cell death in human NT2-N neurons. Pediatr Res. 2006;59(1): 72–77.
  • Yang Y, Zhu X, Chen Y, Wang X, Chen R. p38 and JNK MAPK, but not ERK1/2 MAPK, play important role in colchicine-induced cortical neurons apoptosis. Eur J Pharmacol. 2007;576(1–3):26–33.
  • Medders KE, Sejbuk NE, Maung R, Desai MK, Kaul M. Activation of p38 MAPK is required in monocytic and neuronal cells for HIV glycoprotein 120-induced neurotoxicity. J Immunol. 2010;185(8):4883–4895.
  • Neubert M, Ridder DA, Bargiotas P, Akira S, Schwaninger M. Acute inhibition of TAK1 protects against neuronal death in cerebral ischemia. Cell Death Differ. 2011;18(9):1521–1530.
  • Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature. 1999;397(6718):436–441.
  • Van Rompay KK. Evaluation of antiretrovirals in animal models of HIV infection. Antiviral Res. 2010;85(1):159–175.
  • Gardner MB. Historical perspective. In: Friedman H, Specter S, Bendinelli M, editors. In Vivo Models of HIV Disease and Control. New York, NY: Springer; 2006:1–18.
  • Balzarini J, Vahlenkamp T, Egberink H, et al. Antiretroviral activities of acyclic nucleoside phosphonates (9-[2- phosphonylmethoxyethyl] adenine, 9-[2-phosphonylmethoxyethyl]guanine, [R]-9-[2-phosphonylmethoxypropyl]adenine, and MDL 74,968) in cell cultures and murine sarcoma virus-infected newborn NMRI mice. Antimicrob Agents Chemother. 1997;41(3):611–616.
  • Ruprecht RM, O’Brien LG, Rossoni LD, Nusinoff-Lehrman S. Suppression of mouse viraemia and retroviral disease by 3′-azido-3′-deoxythymidine. Nature. 1986;323(6087):467–469.
  • Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell. 1986;47(3):333–348.
  • Levy JA, Cheng-Mayer C, Dina D, Luciw PA. AIDS retrovirus (ARV-2) clone replicates in transfected human and animal fibroblasts. Science. 1986;232(4753):998–1001.
  • Wu C, Lu Y. High-titre retroviral vector system for efficient gene delivery into human and mouse cells of haematopoietic and lymphocytic lineages. J Gen Virol. 2010;91(Pt 8):1909–1918.
  • Zheng YH, Yu HF, Peterlin BM. Human p32 protein relieves a post-transcriptional block to HIV replication in murine cells. Nat Cell Biol. 2003;5(7):611–618.
  • Winslow BJ, Trono D. The blocks to human immunodeficiency virus type 1 Tat and Rev functions in mouse cell lines are independent. J Virol. 1993;67(4):2349–2354.
  • Goffinet C, Allespach I, Keppler OT. HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription. Proc Natl Acad Sci U S A. 2007;104(3): 1015–1020.
  • Michel N, Goffinet C, Ganter K, et al. Human cyclin T1 expression ameliorates a T-cell-specific transcriptional limitation for HIV in transgenic rats, but is not sufficient for a spreading infection of prototypic R5 HIV-1 strains ex vivo. Retrovirology. 2009;6:2.
  • Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature. 1994;367(6459):188–193.
  • Maung R, Medders KE, Sejbuk NE, Desai MK, Russo R, Kaul M. Genetic knockouts suggest a critical role for HIV co-receptors in models of HIV gp120-induced brain injury. J Neuroimmune Pharmacol. 2012;7(2):306–318.
  • Erichsen D, Lopez AL, Peng H, et al. Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia. J Neuroimmunol. 2003;138(1–2):144–155.
  • Zhang K, Rana F, Silva C, et al. Human immunodeficiency virus type 1 envelope-mediated neuronal death: uncoupling of viral replication and neurotoxicity. J Virol. 2003;77(12):6899–6912.
  • Kim BO, Liu Y, Ruan Y, Xu ZC, Schantz L, He JJ. Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am J Pathol. 2003;162(5): 1693–1707.
  • Power C, Hui E, Vivithanaporn P, Acharjee S, Polyak M. Delineating HIV-associated neurocognitive disorders using transgenic models: the neuropathogenic actions of Vpr. J Neuroimmune Pharmacol. 2012;7(2):319–331.
  • Reid W, Sadowska M, Denaro F, et al. An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci U S A. 2001;98(16):9271–9276.
  • Chang SL, Connaghan KP. Behavioral and molecular evidence for a feedback interaction between morphine and HIV-1 viral proteins. J Neuroimmune Pharmacol. 2012;7(2):332–340.
  • Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738): 367–387.
  • Hayman M, Arbuthnott G, Harkiss G, et al. Neurotoxicity of peptide analogues of the transactivating protein tat from maedi-visna virus and human immunodeficiency virus. Neuroscience. 1993;53(1): 1–6.
  • Yao H, Buch S. Rodent models of HAND and drug abuse: exogenous administration of viral protein(s) and cocaine. J Neuroimmune Pharmacol. 2012;7(2):341–351.
  • Kelschenbach JL, Saini M, Hadas E, et al. Mice chronically infected with chimeric HIV resist peripheral and brain superinfection: a model of protective immunity to HIV. J Neuroimmune Pharmacol. 2012;7(2):380–387.
  • Potash MJ, Chao W, Bentsman G, et al. A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness. Proc Natl Acad Sci U S A. 2005;102(10): 3760–3765.
  • Borkow G. Mouse models for HIV-1 infection. IUBMB Life. 2005;57(12):819–823.
  • Stoddart CA, Reyes RA. Models of HIV-1 disease: a review of current status. Drug Discov Today Dis Models. 2006;3(1):113–119.
  • Denton PW, Estes JD, Sun Z, et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 2008;5(1):e16.
  • Lubin I, Segall H, Marcus H, et al. Engraftment of human peripheral blood lymphocytes in normal strains of mice. Blood. 1994;83(8): 2368–2381.
  • Reisner Y, Dagan S. The Trimera mouse: generating human monoclonal antibodies and an animal model for human diseases. Trends Biotechnol. 1998;16(6):242–246.
  • Denton PW, Garcia JV. Humanized mouse models of HIV infection. AIDS Rev. 2011;13(3):135–148.
  • Gorantla S, Makarov E, Finke-Dwyer J, et al. Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesis. Am J Pathol. 2010;177(6):2938–2949.
  • Dash PK, Gorantla S, Gendelman HE, et al. Loss of neuronal integrity during progressive HIV-1 infection of humanized mice. J Neurosci. 2011;31(9):3148–3157.
  • Gorantla S, Poluektova L, Gendelman HE. Rodent models for HIV-associated neurocognitive disorders. Trends Neurosci. 2012;35(3): 197–208.
  • Gong N, Liu J, Reynolds AD, Gorantla S, Mosley RL, Gendelman HE. Brain ingress of regulatory T cells in a murine model of HIV-1 encephalitis. J Neuroimmunol. 2011;230(1–2):33–41.
  • Sparger EE. FIV as a model for HIV: an overview. In: Friedman H, Specter S, Bendinelli M, editors. In Vivo Models of HIV Disease and Control. New York, NY: Springer; 2006:149–238.
  • Cronn RC, Remington KM, Preston BD, North TW. Inhibition of reverse transcriptase from feline immunodeficiency virus by analogs of 2′-deoxyadenosine-5′-triphosphate. Biochem Pharmacol. 1992;44(7):1375–1381.
  • Hartmann K, Donath A, Beer B, et al. Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet Immunol Immunopathol. 1992;35(1–2): 167–175.
  • Hartmann K, Kuffer M, Balzarini J, et al. Efficacy of the acyclic nucleoside phosphonates (S)-9-(3-fluoro-2-phosphonylmethoxypropyl) adenine (FPMPA) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against feline immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17(2):120–128.
  • North TW, North GL, Pedersen NC. Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome. Antimicrob Agents Chemother. 1989;33(6):915–919.
  • North TW, Cronn RC, Remington KM, Tandberg RT. Direct comparisons of inhibitor sensitivities of reverse transcriptases from feline and human immunodeficiency viruses. Antimicrob Agents Chemother. 1990;34(8):1505–1507.
  • Vahlenkamp TW, De Ronde A, Balzarini J, et al. (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection. Antimicrob Agents Chemother. 1995;39(3):746–749.
  • Auwerx J, Esnouf R, De Clercq E, Balzarini J. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors. Mol Pharmacol. 2004;65(1):244–251.
  • Dean GA, Reubel GH, Moore PF, Pedersen NC. Proviral burden and infection kinetics of feline immunodeficiency virus in lymphocyte subsets of blood and lymph node. J Virol. 1996;70(8):5165–5169.
  • Nath BM, Schumann KE, Boyer JD. The chimpanzee and other nonhuman primate models in HIV-1 vaccine research. Trends Microbiol. 2000;8(9):426–431.
  • Novembre FJ, de Rosayro J, Nidtha S, et al. Rapid CD4(+) T-cell loss induced by human immunodeficiency virus type 1(NC) in uninfected and previously infected chimpanzees. J Virol. 2001;75(3): 1533–1539.
  • Novembre FJ, Saucier M, Anderson DC, et al. Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1. J Virol. 1997;71(5):4086–4091.
  • Frumkin LR, Agy MB, Coombs RW, et al. Acute infection of Macaca nemestrina by human immunodeficiency virus type 1. Virology. 1993;195(2):422–431.
  • Thippeshappa R, Polacino P, Yu Kimata MT, et al. Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1. J Virol. 2011;85(8):3767–3779.
  • Hatziioannou T, Ambrose Z, Chung NP, et al. A macaque model of HIV-1 infection. Proc Natl Acad Sci U S A. 2009;106(11): 4425–4429.
  • Livartowski J, Dormont D, Boussin F, et al. Clinical and virological aspects of HIV2 infection in rhesus monkeys. Cancer Detect Prev. 1992;16(5–6):341–345.
  • Locher CP, Witt SA, Herndier BG, Tenner-Racz K, Racz P, Levy JA. Baboons as an animal model for human immunodeficiency virus pathogenesis and vaccine development. Immunol Rev. 2001;183: 127–140.
  • Putkonen P, Bottiger B, Warstedt K, Thorstensson R, Albert J, Biberfeld G. Experimental infection of cynomolgus monkeys (Macaca fascicularis) with HIV-2. J Acquir Immune Defic Syndr. 1989;2(4):366–373.
  • Pandrea I, Silvestri G, Apetrei C. AIDS in African nonhuman primate hosts of SIVs: a new paradigm of SIV infection. Curr HIV Res. 2009;7(1):57–72.
  • Silvestri G, Sodora DL, Koup RA, et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity. 2003;18(3):441–452.
  • Silvestri G, Fedanov A, Germon S, et al. Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabey and nonnatural rhesus macaque hosts. J Virol. 2005;79(7):4043–4054.
  • Gardner MB. Simian AIDS: an historical perspective. J Med Primatol. 2003;32(4–5):180–186.
  • Chahroudi A, Bosinger SE, Vanderford TH, Paiardini M, Silvestri G. Natural SIV hosts: showing AIDS the door. Science. 2012;335(6073): 1188–1193.
  • Daniel MD, Letvin NL, King NW, et al. Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science. 1985;228(4704): 1201–1204.
  • Veazey RS, DeMaria M, Chalifoux LV, et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science. 1998;280(5362):427–431.
  • Haigwood NL, Montefiori DC, Sutton WF, et al. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol. 2004;78(11):5983–5995.
  • Lifson JD, Nowak MA, Goldstein S, et al. The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol. 1997;71(12):9508–9514.
  • Watson A, Ranchalis J, Travis B, et al. Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol. 1997;71(1):284–290.
  • Ambrose Z, Kewalramani VN, Bieniasz PD, Hatziioannou T. HIV/ AIDS: in search of an animal model. Trends Biotechnol. 2007;25(8): 333–337.
  • Shibata R, Kawamura M, Sakai H, Hayami M, Ishimoto A, Adachi A. Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J Virol. 1991;65(7):3514–3520.
  • Li J, Lord CI, Haseltine W, Letvin NL, Sodroski J. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J Acquir Immune Defic Syndr. 1992;5(7):639–646.
  • Reimann KA, Li JT, Veazey R, et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol. 1996;70(10): 6922–6928.
  • Luciw PA, Pratt-Lowe E, Shaw KE, Levy JA, Cheng-Mayer C. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc Natl Acad Sci U S A. 1995;92(16):7490–7494.
  • Lu Y, Salvato MS, Pauza CD, et al. Utility of SHIV for testing HIV-1 vaccine candidates in macaques. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12(2):99–106.
  • Harouse JM, Gettie A, Eshetu T, et al. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol. 2001;75(4): 1990–1995.
  • Song RJ, Chenine AL, Rasmussen RA, et al. Molecularly cloned SHIV-1157ipd3N4: a highly replication-competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J Virol. 2006;80(17):8729–8738.
  • Kraft Z, Derby NR, McCaffrey RA, et al. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J Virol. 2007;81(12):6402–6411.
  • Ruprecht RM, Baba TW, Liska V, et al. Oral SIV, SHIV, and HIV type 1 infection. AIDS Res Hum Retroviruses. 1998;14(Suppl 1): S97–S103.
  • Lederman MM, Veazey RS, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science. 2004;306(5695):485–487.
  • Lagenaur LA, Sanders-Beer BE, Brichacek B, et al. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol. 2011;4(6):648–657.
  • Uberla K, Stahl-Hennig C, Bottiger D, et al. Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci U S A. 1995;92(18): 8210–8214.
  • Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther. 2004;9(1):57–65.
  • Ambrose Z, Boltz V, Palmer S, Coffin JM, Hughes SH, Kewalramani VN. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J Virol. 2004;78(24):13553–13561.
  • Ishimatsu M, Suzuki H, Akiyama H, Miura T, Hayami M, Ido E. Construction of a novel SHIV having an HIV-1-derived protease gene and its infection to rhesus macaques: a useful tool for in vivo efficacy tests of protease inhibitors. Microbes Infect. 2007;9(4):475–482.
  • Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999;283(5403):857–860.
  • Williams K, Burdo TH. Monocyte mobilization, activation markers, and unique macrophage populations in the brain: observations from SIV infected monkeys are informative with regard to pathogenic mechanisms of HIV infection in humans. J Neuroimmune Pharmacol. 2012;7(2):363–371.
  • Weed M, Adams RJ, Hienz RD, et al. SIV/macaque model of HIV infection in cocaine users: minimal effects of cocaine on behavior, virus replication, and CNS inflammation. J Neuroimmune Pharmacol. 2012;7(2):401–411.
  • Winkler JM, Chaudhuri AD, Fox HS. Translating the brain transcriptome in neuroAIDS: from non-human primates to humans. J Neuroimmune Pharmacol. 2012;7(2):372–379.
  • Yelamanchili SV, Chaudhuri AD, Chen LN, Xiong H, Fox HS. MicroRNA-21 dysregulates the expression of MEF2C in neurons in monkey and human SIV/HIV neurological disease. Cell Death Dis. 2010;1:e77.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.